For laboratory research use only. Not for human or veterinary use.

Same-day dispatch on orders before 4 PM ET · Support

NAD+: discovery, structure and research history

Research Library › Mitochondrial & Coenzyme

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme, not a peptide: a dinucleotide that carries electrons in the oxidation-reduction reactions of cellular metabolism. It was discovered in 1906 by British biochemists Arthur Harden and William John Young as a heat-stable factor in yeast juice. As of 22 Oct 2026, NAD+ is not an FDA-approved drug and is listed by FDA as under evaluation for pharmacy compounding.

Key facts

TypeCoenzyme (dinucleotide); not a peptide
Full nameNicotinamide adenine dinucleotide, oxidized form
First described1906, Harden and Young, Proceedings of the Royal Society B
Discovered byArthur Harden and William John Young; structure work by Hans von Euler-Chelpin
Natural roleElectron carrier in redox reactions in nearly every living cell
Regulatory status (Oct 2026)Not FDA-approved as a drug; under FDA evaluation for 503A compounding

Who discovered it

In 1906 Arthur Harden and William John Young, working in London on how yeast ferments sugar, found that boiled and filtered yeast juice contained a heat-stable factor needed for fermentation. They called it a “coferment”; it is now known as NAD+ [1, 2].

Swedish-German chemist Hans von Euler-Chelpin later showed the factor was a nucleotide. Harden and von Euler-Chelpin shared the 1929 Nobel Prize in Chemistry for their work on sugar fermentation and its enzymes [3].

Structure and natural role

NAD+ is not a peptide. It is a dinucleotide: two nucleotides, one carrying nicotinamide and one carrying adenine, joined through their phosphate groups. It cycles between an oxidized form (NAD+) and a reduced form (NADH), accepting and donating electrons in the metabolic reactions found in nearly every cell [4].

Cells make NAD+ through several routes. In 2004 Charles Brenner’s group identified nicotinamide riboside (NR) as a nutrient precursor and described the kinase pathway that converts it, establishing an additional route to NAD+ in yeast and humans [5]. Nicotinamide mononucleotide (NMN) is another precursor [4].

Why it is studied

For most of the twentieth century NAD+ was studied as a core piece of energy metabolism. Starting in the 2010s, mouse studies from laboratories including those of Shin-ichiro Imai and David Sinclair examined how cellular NAD+ levels change with age, which drew new research attention to the molecule and its precursors [6, 7]. This later work focused on the enzymes that make and consume NAD+, including the sirtuin family. A 2026 narrative review found no randomized placebo-controlled trials of infused NAD+ and described its clinical use as investigational [8].

Research timeline

  • 1906: Harden and Young describe the heat-stable “coferment” in yeast juice [1, 2]
  • 1929: Harden and von Euler-Chelpin share the Nobel Prize in Chemistry [3]
  • 2004: Brenner’s group describes the NR route to NAD+ [5]
  • 2022: FDA takes the position that NMN is excluded from dietary supplements [9, 10]
  • Sep 2025: FDA reverses that position on NMN [9, 10]
  • May 2026: FDA lists NAD+ as under evaluation for 503A compounding [11]

Regulatory status as of October 2026

As of 22 Oct 2026, NAD+ is not an FDA-approved drug. On FDA’s list of bulk drug substances nominated for 503A pharmacy compounding, updated 14 May 2026, NAD+ appears in Category 1, the group of nominated substances still under evaluation, with no final decision [11]. Category 1 placement is an interim status, not an endorsement or approval.

The precursors NR and NMN are sold in the United States as dietary supplement ingredients. In 2022 FDA said NMN could not be a supplement because it had first been investigated as a drug; after a trade group sued, FDA reversed that position in a September 2025 response to a citizen petition [9, 10]. NAD+ is not named on the World Anti-Doping Agency’s 2026 Prohibited List [12].

Available from Kalibra Labs

Supplied as a lyophilized research material with a Certificate of Analysis matched to each lot number.

Look up a Certificate of Analysis by lot number →

Frequently asked questions

Who discovered NAD+?

Arthur Harden and William John Young discovered NAD+ in 1906 as a heat-stable factor in yeast juice; Hans von Euler-Chelpin later characterized it as a nucleotide.

Is NAD+ a peptide?

No. NAD+ is a coenzyme made of two nucleotides, not a chain of amino acids.

Is NAD+ FDA approved?

No. As of October 2026 NAD+ is not an FDA-approved drug, and FDA lists it as under evaluation for pharmacy compounding.

What does NAD stand for?

NAD stands for nicotinamide adenine dinucleotide; the plus sign marks the oxidized form.

Are NR and NMN the same as NAD+?

No. Nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are smaller precursor molecules that cells can convert into NAD+.

Sources

  1. Harden A, Young WJ. The alcoholic ferment of yeast-juice. Proc R Soc Lond B. 1906;77(519):405-420. doi:10.1098/rspb.1906.0029. Link
  2. Harden A, Young WJ. The alcoholic ferment of yeast-juice. Part II. The coferment of yeast-juice. Proc R Soc Lond B. 1906;78(526):369-375. Link
  3. NobelPrize.org. The Nobel Prize in Chemistry 1929: Arthur Harden and Hans von Euler-Chelpin. Link
  4. Wikipedia. Nicotinamide adenine dinucleotide: History (citing Harden & Young, Proc R Soc Lond B 1906, and Bieganowski & Brenner, Cell 2004). Link
  5. Bieganowski P, Brenner C. Discoveries of nicotinamide riboside as a nutrient and conserved NRK genes establish a Preiss-Handler independent route to NAD+ in fungi and humans. Cell. 2004;117(4):495-502. doi:10.1016/S0092-8674(04)00416-7. Link
  6. Wikipedia. Nicotinamide mononucleotide (research history incl. Mills et al., Cell Metab 2016, Imai lab; US regulatory status). Link
  7. Wikipedia. David Andrew Sinclair (NMN research; Gomes et al., Cell 2013). Link
  8. Alangari A, Arif J, Al Qureshah F, Alkhodairy F. Narrative review of intravenous NAD+ and NAD+ precursors in wellness and translational medicine. Front Aging. 2026;7. doi:10.3389/fragi.2026.1887175. Link
  9. U.S. FDA. Response to citizen petition, Docket FDA-2023-P-0872 (NMN not excluded from the dietary supplement definition). 29 Sep 2025. Link
  10. Daniells S. FDA declares NMN lawful in dietary supplements. NutraIngredients, 30 Sep 2025. Link
  11. FDA. Bulk drug substances nominated for use in compounding under section 503A (Categories 1-3). Updated 14 May 2026. Link
  12. World Anti-Doping Agency. 2026 Prohibited List. Link

Regulatory information current as of October 2026. Reviewed by the Kalibra Labs editorial team.

For Research Use Only. Kalibra Labs supplies this compound as a lyophilized research material for in-vitro laboratory use. It is not for human or veterinary use and not for use in diagnostic or therapeutic procedures. This page is a scientific and historical reference; it is not medical advice and makes no claim about use in people or animals.

0
Your Cart
Empty CartYour cart is emptyReturn to Shop
Scroll to Top